A Bruton's Tyrosine Kinase Inhibitor Prevents Antigen-Driven B Cell Activation In Vivo

被引：0

作者：

Benson, Micah ^{[1
]}

Rodriguez, Varenka A. ^{[1
]}

Andreyeva, Tatyana ^{[1
]}

Keegan, Sean ^{[1
]}

Springer, John R. ^{[1
]}

Schnute, Mark E. ^{[1
]}

Dunussi-Joannopoulos, Kyri ^{[1
]}

Nickerson-Nutter, Cheryl L. ^{[1
]}

Rankin, Andrew L. ^{[1
]}

Ruzek, Melanie ^{[1
]}

Douhan, John, III ^{[1
]}

机构：

[1] Pfizer Inc, Cambridge, MA USA

来源：

ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1758

引用

页码：S689 / S689

页数：1

共 50 条

[21] Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies
Andrew Aw
Jennifer R. Brown
Drugs & Aging, 2017, 34 : 509 - 527
[22] A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2
Takata, M
Kurosaki, T
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (01): : 31 - 40
[23] Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
Anna Turetsky
Eunha Kim
Rainer H. Kohler
Miles A. Miller
Ralph Weissleder
Scientific Reports, 4
[24] Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
Turetsky, Anna
Kim, Eunha
Kohler, Rainer H.
Miller, Miles A.
Weissleder, Ralph
SCIENTIFIC REPORTS, 2014, 4
[25] Bruton's tyrosine kinase is essential for human B cell tolerance
Ng, YS
Wardemann, H
Chelnis, J
Cunningham-Rundles, C
Meffre, E
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (07): : 927 - 934
[26] Bruton's tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement
Petro, JB
Rahman, SMJ
Ballard, DW
Khan, WN
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (10): : 1745 - 1753
[27] MONITORING B CELL ACTIVATION BY FLOW CYTOMETRIC DETECTION OF PHOSPHORYLATED BRUTON'S TYROSINE KINASE (BTK)
Li, X.
Marchini, T.
Westermann, D.
Wolf, D.
ATHEROSCLEROSIS, 2023, 379 : S43 - S44
[28] BRUTON'S TYROSINE KINASE INHIBITION TO SUPPRESS MAST CELL ACTIVATION IN ATHEROSCLEROSIS
Hemme, E.
Delfos, L.
Depuydt, M. A. C.
Kleijn, M. N. A. Bernabe
Schaftenaar, F. H.
Foks, A. C.
Kuiper, J.
Bot, I.
ATHEROSCLEROSIS, 2022, 355 : E100 - E100
[29] Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
Abbas, Hussein A.
Wierda, William G.
FRONTIERS IN ONCOLOGY, 2021, 11
[30] Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies
Marostica, Eleonora
Sukbuntherng, Juthamas
Loury, David
Jong, Jan D.
de Trixhie, Xavier Woot
Vermeulen, An
de Nicolao, Giuseppe
O'Brien, Susan
Byrd, John C.
Advani, Ranjana
McGreivy, Jesse
Poggesi, Italo
CANCER RESEARCH, 2014, 74 (19)

← 1 2 3 4 5 →